A Retrospective Cohort Study of the 2018 Angiotensin Receptor Blocker Recalls and Subsequent Drug Shortages in Patients With Hypertension

Background Valsartan was recalled by the US Food and Drug Administration in July 2018 for carcinogenic impurities, resulting in a drug shortage and management challenges for valsartan users. The influence of the valsartan recall on clinical outcomes is unknown. We compared the risk of adverse events...

Descripción completa

Detalles Bibliográficos

Autores principales:	Joshua W. Devine, Mina Tadrous, Inmaculada Hernandez, Katherine Callaway Kim, Scott D. Rothenberger, Nandita Mukhopadhyay, Walid F. Gellad, Katie J. Suda
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wiley 2024-01-01
Colección:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Materias:	drug recall drug shortages hypertension valsartan
Acceso en línea:	https://www.ahajournals.org/doi/10.1161/JAHA.123.032266
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!